Of the over 17,000 patients enrolled in the SELECT trial, about 25% had heart failure, of which about one-third had HFrEF
Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial
Similarly, Wegovy, initially known for its weight loss effects, was approved in August 2025 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
Store your vials in the refrigerator between 3646F (28C), never in the freezer
Whether Gala GLP-1 is the right fit depends on factors only you and your licensed provider can evaluate: current health status, medical history, weight loss goals, budget, risk tolerance, and individual eligibility